NZ608384A - Biomarkers of renal injury - Google Patents
Biomarkers of renal injuryInfo
- Publication number
- NZ608384A NZ608384A NZ608384A NZ60838411A NZ608384A NZ 608384 A NZ608384 A NZ 608384A NZ 608384 A NZ608384 A NZ 608384A NZ 60838411 A NZ60838411 A NZ 60838411A NZ 608384 A NZ608384 A NZ 608384A
- Authority
- NZ
- New Zealand
- Prior art keywords
- patient
- value
- biomarker
- prognosis
- renal injury
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 5
- 206010061481 Renal injury Diseases 0.000 title 1
- 238000004393 prognosis Methods 0.000 abstract 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 2
- 239000013060 biological fluid Substances 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- 229960003160 hyaluronic acid Drugs 0.000 abstract 2
- 238000011084 recovery Methods 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38623010P | 2010-09-24 | 2010-09-24 | |
| US13/235,005 US10557856B2 (en) | 2010-09-24 | 2011-09-16 | Biomarkers of renal injury |
| PCT/US2011/052082 WO2012040073A2 (en) | 2010-09-24 | 2011-09-19 | Biomarkers of renal injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ608384A true NZ608384A (en) | 2014-12-24 |
Family
ID=45871234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ608384A NZ608384A (en) | 2010-09-24 | 2011-09-19 | Biomarkers of renal injury |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10557856B2 (enExample) |
| EP (1) | EP2619577B1 (enExample) |
| JP (1) | JP5998143B2 (enExample) |
| KR (1) | KR101981745B1 (enExample) |
| CN (1) | CN103189745B (enExample) |
| AU (1) | AU2011305786B2 (enExample) |
| BR (1) | BR112013006935B1 (enExample) |
| CA (1) | CA2811658C (enExample) |
| EA (1) | EA030622B1 (enExample) |
| MX (1) | MX365029B (enExample) |
| NZ (1) | NZ608384A (enExample) |
| WO (1) | WO2012040073A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| MX2011011517A (es) | 2009-04-29 | 2012-06-19 | Amarin Corp Plc | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. |
| LT2443246T (lt) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130282390A1 (en) * | 2012-04-20 | 2013-10-24 | International Business Machines Corporation | Combining knowledge and data driven insights for identifying risk factors in healthcare |
| WO2013184868A1 (en) * | 2012-06-06 | 2013-12-12 | The Cleveland Clinic Foundation | Prediction of acute kidney injury from a post-surgical metabolic blood panel |
| AU2013329451B2 (en) * | 2012-10-08 | 2018-08-09 | Vifor (International) Ltd. | Potassium-binding agents for treating hypertension and hyperkalemia |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| AU2014227891A1 (en) * | 2013-03-15 | 2015-10-08 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US10126305B2 (en) | 2013-06-25 | 2018-11-13 | University of Pittsburg—Of the Commonwealth System of Higher Education | Proteomic biomarkers of sepsis in elderly patients |
| GB201317621D0 (en) * | 2013-10-04 | 2013-11-20 | Randox Teoranta | Kidney disease biomarker |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US20180038873A1 (en) * | 2015-02-05 | 2018-02-08 | University Of Florida Research Foundation, Inc. | Use of nhe3 as a biomarker for radiation biodosimetry |
| EP3196791A1 (de) * | 2017-05-02 | 2017-07-26 | Siemens Healthcare GmbH | Verfahren zur unterstützung von medizinischem personal, unterstützungssystem, computerprogramm und datenträger |
| US11771113B2 (en) | 2017-05-31 | 2023-10-03 | Mars, Incorporated | Methods of diagnosing and treating chronic kidney disease |
| US11026625B2 (en) * | 2017-08-08 | 2021-06-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| WO2019144081A1 (en) | 2018-01-19 | 2019-07-25 | Mars, Incorporated | Biomarkers and classification algorithms for chronic kidney disease in cats |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US20190317090A1 (en) * | 2018-04-12 | 2019-10-17 | Children's Hospital Medical Center | Compositions and methods for forecasting response to lupus nephritis (ln)therapy |
| US10978176B2 (en) * | 2018-06-29 | 2021-04-13 | pulseData Inc. | Machine learning systems and methods for predicting risk of renal function decline |
| US20210327589A1 (en) | 2018-07-14 | 2021-10-21 | Mars, Incorporated | Biomarkers and test models for chronic kidney disease |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| CN109754878B (zh) * | 2018-11-30 | 2023-06-20 | 平安科技（深圳）有限公司 | 慢性肾病筛查方法、装置、设备及存储介质 |
| CN109738931B (zh) * | 2018-12-18 | 2022-06-17 | 上海瑞派益尔科技有限公司 | 一种肾小球滤过率检测设备 |
| US11350887B2 (en) | 2019-08-07 | 2022-06-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for detection of potential health issues |
| CN110596370B (zh) * | 2019-09-17 | 2023-03-24 | 广州医科大学附属第五医院 | 一种检测细菌尿路感染的酶联免疫吸附试剂盒及其应用 |
| CN114980973A (zh) | 2019-11-12 | 2022-08-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| CN110923310B (zh) * | 2019-12-24 | 2023-04-18 | 广州市妇女儿童医疗中心 | 用于指导肾病综合征cyp3a5表达型患儿使用他克莫司的多态性位点 |
| CN110904219B (zh) * | 2019-12-24 | 2023-04-18 | 广州市妇女儿童医疗中心 | Myh9及ctla4基因多态性位点在指导肾病综合征患儿使用他克莫司中的应用 |
| CA3178400A1 (en) | 2020-06-01 | 2021-12-09 | Ilias TAGKOPOULOS | System and method for chronic kidney disease of a dog |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| RU2761738C1 (ru) * | 2021-06-07 | 2021-12-13 | Алина Владимировна Еремеева | Способ отбора детей с дебютом острого пиелонефрита для проведения курса противорецидивной терапии пиелонефрита |
| WO2022261513A1 (en) * | 2021-06-10 | 2022-12-15 | Kang Zhang | Methods and systems of detecting and predicting chronic kidney disease and type 2 diabetes using deep learning models |
| WO2024040225A2 (en) * | 2022-08-19 | 2024-02-22 | The Johns Hopkins University | Diagnosis and treatment of acute kidney injury |
| US20250001158A1 (en) * | 2023-06-28 | 2025-01-02 | Abiomed, Inc. | Cardiorenal syndrome (crs) therapy systems and methods |
| CN117373584B (zh) * | 2023-12-08 | 2024-03-12 | 北京大学第一医院 | 一种急性肾损伤的动态预测方法及系统 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| ATE177841T1 (de) | 1991-04-10 | 1999-04-15 | Biosite Diagnostics Inc | ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6350571B1 (en) | 1996-02-01 | 2002-02-26 | Vinata B. Lokeshwar | Methods for detection and evaluation of bladder cancer |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| CN101393165A (zh) * | 2007-09-20 | 2009-03-25 | 复旦大学附属华山医院 | 一种检测糖尿病肾病血清标本中差异表达的蛋白质谱的方法 |
| KR20100122495A (ko) * | 2008-02-29 | 2010-11-22 | 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 | 급성 신장 장해 및 예후 추정용 바이오마커 및 그 용도 |
| US20090239242A1 (en) | 2008-03-18 | 2009-09-24 | Biotrin Intellectual Properties Limited | Method for the early identification and prediction of kidney injury |
| NZ610356A (en) * | 2008-08-28 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9057735B2 (en) * | 2008-08-29 | 2015-06-16 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8501489B2 (en) * | 2008-09-26 | 2013-08-06 | University of Pittsburgh—of the Commonwealth System of Higher Education | Urinary biomarkers to predict long-term dialysis |
| CN104020284B (zh) | 2008-10-21 | 2016-08-24 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| ES2528799T3 (es) * | 2008-11-22 | 2015-02-12 | Astute Medical, Inc. | Métodos para el pronóstico de insuficiencia renal aguda |
| CN102792161B (zh) * | 2009-08-28 | 2014-11-12 | 阿斯图特医药公司 | 肾损伤和肾衰竭的诊断及预后的方法及组合物 |
| JP5763098B2 (ja) * | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
-
2011
- 2011-09-16 US US13/235,005 patent/US10557856B2/en active Active
- 2011-09-19 NZ NZ608384A patent/NZ608384A/en not_active IP Right Cessation
- 2011-09-19 EA EA201390439A patent/EA030622B1/ru not_active IP Right Cessation
- 2011-09-19 CA CA2811658A patent/CA2811658C/en active Active
- 2011-09-19 EP EP11827278.0A patent/EP2619577B1/en active Active
- 2011-09-19 JP JP2013530205A patent/JP5998143B2/ja active Active
- 2011-09-19 AU AU2011305786A patent/AU2011305786B2/en active Active
- 2011-09-19 MX MX2013003321A patent/MX365029B/es active IP Right Grant
- 2011-09-19 CN CN201180053315.7A patent/CN103189745B/zh active Active
- 2011-09-19 WO PCT/US2011/052082 patent/WO2012040073A2/en not_active Ceased
- 2011-09-19 KR KR1020137009232A patent/KR101981745B1/ko not_active Expired - Fee Related
- 2011-09-19 BR BR112013006935-0A patent/BR112013006935B1/pt not_active IP Right Cessation
-
2020
- 2020-01-15 US US16/743,610 patent/US11693014B2/en active Active
-
2023
- 2023-05-22 US US18/321,405 patent/US20240118289A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011305786A1 (en) | 2013-04-11 |
| EP2619577A2 (en) | 2013-07-31 |
| US20200150132A1 (en) | 2020-05-14 |
| CN103189745A (zh) | 2013-07-03 |
| BR112013006935A2 (pt) | 2017-05-30 |
| CA2811658C (en) | 2021-03-30 |
| EP2619577B1 (en) | 2017-08-16 |
| CA2811658A1 (en) | 2012-03-29 |
| KR20140001863A (ko) | 2014-01-07 |
| US11693014B2 (en) | 2023-07-04 |
| JP2013539030A (ja) | 2013-10-17 |
| AU2011305786B2 (en) | 2015-04-23 |
| EA201390439A1 (ru) | 2013-09-30 |
| EA030622B1 (ru) | 2018-09-28 |
| US20240118289A1 (en) | 2024-04-11 |
| KR101981745B1 (ko) | 2019-05-27 |
| EP2619577A4 (en) | 2014-04-30 |
| US10557856B2 (en) | 2020-02-11 |
| CN103189745B (zh) | 2018-05-01 |
| MX2013003321A (es) | 2013-10-25 |
| WO2012040073A2 (en) | 2012-03-29 |
| MX365029B (es) | 2019-05-21 |
| WO2012040073A3 (en) | 2012-06-14 |
| BR112013006935B1 (pt) | 2021-02-23 |
| JP5998143B2 (ja) | 2016-09-28 |
| US20120077690A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ608384A (en) | Biomarkers of renal injury | |
| NZ605698A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ705411A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ593514A (en) | p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer | |
| GB201300533D0 (en) | Methods of monitoring conditions by sequence analysis | |
| MX341517B (es) | Biomarcadores de cancer pancreatico y usos de los mismos. | |
| NZ700695A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2013113012A3 (en) | Methods for profiling and quantitating cell-free rna | |
| NZ624609A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ594771A (en) | Methods and compositions for diagnosis and prognosis of renal injury and failure | |
| NZ628843A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| MX2020004617A (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| EP2596132A4 (en) | METHODS OF DETECTING SIGNATURES OF DISEASES OR PATHOLOGIES IN BIOLOGICAL LIQUIDS | |
| NZ591437A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2010096154A3 (en) | Compositions and methods for diagnosis and prognosis of colorectal cancer | |
| IN2015DN01855A (enExample) | ||
| EP3734280A3 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| MX2014004860A (es) | Biomarcadores de cancer de pulmon y usos de los mismos. | |
| HK1259001A1 (zh) | 癌症的预後和诊断方法 | |
| NZ624614A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ606124A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ630621A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ608316A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| NZ594772A (en) | Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c | |
| NZ628085A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2016 BY HENRY HUGHES IP LIMITED Effective date: 20150915 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2017 BY HENRY HUGHES IP LIMITED Effective date: 20160919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2018 BY CPA GLOBAL Effective date: 20170803 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2019 BY CPA GLOBAL Effective date: 20180802 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2020 BY CPA GLOBAL Effective date: 20190808 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2021 BY CPA GLOBAL Effective date: 20200806 |
|
| LAPS | Patent lapsed |